HER2 Support Group Forums

HER2 Support Group Forums (https://her2support.org/vbulletin/index.php)
-   Articles of Interest (https://her2support.org/vbulletin/forumdisplay.php?f=31)
-   -   100% inhibition of neovascularization of breast cancer in mice with DNA encoding AMA (https://her2support.org/vbulletin/showthread.php?t=24575)

Lani 07-15-2006 05:37 AM

100% inhibition of neovascularization of breast cancer in mice with DNA encoding AMA
 
1: Cancer Gene Ther. 2006 Jul 14; [Epub ahead of print] Links

Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist.

Miseki T, Kawakami H, Natsuizaka M, Darmanin S, Cui HY, Chen J, Fu Q, Okada F, Shindo M, Higashino F, Asaka M, Hamuro J, Kobayashi M.

[1] 1Division of Cancer Biology, Institute for Genetic Medicine, Hokkaido University, Hokkaido, Japan [2] 2Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.

We have recently reported that the intra-tumoral injection of adrenomedullin (AM) antagonist (AMA; AM (22-52)) peptides significantly reduced the in vivo growth of a pancreatic cancer cell line in severely combined immunodeficient (SCID) mice. In the present study, we examined the effects of intra-tumoral and intra-muscular transfers of naked DNA encoding AMA on the in vivo growth of cancer cell lines. We demonstrate that these treatments induce the regression of a pancreatic cancer cell line and a breast cancer cell line inoculated in SCID mice. Furthermore, CD31-positive cells disappear completely from tumor tissues, following treatment, indicating that neo-vascularization is entirely inhibited. These results suggest that the intra-tumoral or intra-muscular transfer of naked DNA encoding AMA might be a promising alternative modality for treating human cancers.Cancer Gene Therapy advance online publication, 14 July 2006; doi:10.1038/sj.cgt.7700979.

PMID: 16841081 [PubMed - as supplied by publisher]


All times are GMT -7. The time now is 11:36 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021